NasdaqCM:RLMDPharmaceuticals
A Look At Relmada Therapeutics (RLMD) Valuation After NDV‑01 Phase 2 Bladder Cancer Data
Phase 2 NDV-01 data and what it could mean for Relmada Therapeutics (RLMD)
Relmada Therapeutics (RLMD) has drawn fresh attention after reporting 12 month interim Phase 2 data for NDV-01 in high risk non muscle invasive bladder cancer, showing strong complete response rates and a favorable safety profile.
See our latest analysis for Relmada Therapeutics.
The NDV-01 update and recent Leerink healthcare conference appearance came alongside a sharp shift in sentiment, with Relmada Therapeutics’ 1...